Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPCX
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
CTRA
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.69% |
| 2 | Industrials | 9.96% |
| 3 | Consumer Discretionary | 8.03% |
| 4 | Healthcare | 7.46% |
| 5 | Financials | 6.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2301
Sable Offshore Corp
SOC
$979M
| $667K | ﹤0.01% |
216,690
+72,848
| +51% | +$927K |
|
2302
Hillman Solutions
HLMN
$1.63B
| $667K | ﹤0.01% |
78,986
-47,189
| -37% | -$375K |
|
2303
Mizuho Financial
MFG
$125B
| $667K | ﹤0.01% |
69,582
+43,372
| +165% | +$390K |
|
|
PBLS
2304
Parabilis Medicines Inc
PBLS
$4.86B
| $664K | ﹤0.01% |
+24,264
| New | +$670K |
|
2305
Unusual Machines
UMAC
$1.37B
| $664K | ﹤0.01% |
29,777
+17,044
| +134% | +$316K |
|
2306
Fluor
FLR
$7.01B
| $664K | ﹤0.01% |
12,672
-761,814
| -98% | -$37.3M |
|
2307
Dave Inc Warrants
DAVEW
$18.4M
| $662K | ﹤0.01% |
+278,336
| New | +$244K |
|
2308
Ingersoll Rand
IR
$31.2B
| $662K | ﹤0.01% |
8,079
-2,106
| -21% | -$163K |
|
2309
iRhythm Holdings
IRTC
$4.24B
| $662K | ﹤0.01% |
5,563
-188,866
| -97% | -$22M |
|
2310
POSCO
PKX
$17.3B
| $660K | ﹤0.01% |
+12,846
| New | +$880K |
|
2311
T. Rowe Price
TROW
$23.8B
| $658K | ﹤0.01% |
+5,790
| New | +$592K |
|
2312
VICI Properties
VICI
$29.2B
| $658K | ﹤0.01% |
24,791
-104,563
| -81% | -$2.93M |
|
2313
PUT
Lemonade
LMND
$4.13B
| $657K | ﹤0.01% |
+10,100
| New | +$591K |
|
2314
Nurix Therapeutics
NRIX
$2.77B
| $657K | ﹤0.01% |
+27,066
| New | +$461K |
|
|
ABTC
2315
American Bitcoin Corp
ABTC
$577M
| $656K | ﹤0.01% |
64,204
+38,607
| +151% | +$591K |
|
2316
Xylem
XYL
$26.5B
| $656K | ﹤0.01% |
5,547
+1,533
| +38% | +$177K |
|
2317
CALL
Revolution Medicines
RVMD
$44.9B
| $655K | ﹤0.01% |
3,500
-46,500
| -93% | -$6.79M |
|
|
SPRB
2318
Spruce Biosciences
SPRB
$148M
| $655K | ﹤0.01% |
12,138
-27,862
| -70% | -$1.56M |
|
|
PCTTW
2319
PureCycle Technologies Inc Warrant
PCTTW
| $654K | ﹤0.01% |
251,400
+196,200
| +355% | +$459K |
|
2320
CALL
LyondellBasell Industries
LYB
$21.8B
| $653K | ﹤0.01% |
12,400
-5,500
| -31% | -$380K |
|
2321
Stoke Therapeutics
STOK
$2.08B
| $652K | ﹤0.01% |
19,939
-3,939
| -16% | -$126K |
|
2322
Equinor
EQNR
$102B
| $652K | ﹤0.01% |
+20,764
| New | +$776K |
|
2323
Cincinnati Financial
CINF
$25.8B
| $650K | ﹤0.01% |
3,509
+1,180
| +51% | +$196K |
|
2324
CALL
Trip.com Group
TCOM
$29B
| $649K | ﹤0.01% |
16,300
-13,300
| -45% | -$659K |
|
|
XRN
2325
Chiron Real Estate Inc
XRN
$492M
| $645K | ﹤0.01% |
+17,197
| New | +$610K |
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $7.14B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 9.7% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.